Zacks Investment Management Purchases New Shares in ADMA Biologics, Inc. (NASDAQ:ADMA)

Zacks Investment Management acquired a new position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 288,009 shares of the biotechnology company's stock, valued at approximately $5,757,000. Zacks Investment Management owned approximately 0.12% of ADMA Biologics as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of ADMA. USA Financial Formulas lifted its holdings in shares of ADMA Biologics by 8.6% during the third quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company's stock valued at $136,000 after purchasing an additional 539 shares during the last quarter. Vontobel Holding Ltd. lifted its stake in ADMA Biologics by 7.0% during the third quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company's stock valued at $273,000 after buying an additional 888 shares in the last quarter. Hollencrest Capital Management acquired a new position in shares of ADMA Biologics in the third quarter worth about $30,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of ADMA Biologics by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company's stock worth $163,000 after buying an additional 1,509 shares during the period. Finally, Larson Financial Group LLC purchased a new position in shares of ADMA Biologics in the third quarter worth approximately $31,000. Institutional investors and hedge funds own 75.68% of the company's stock.

Insider Transactions at ADMA Biologics

In other news, CFO Brad L. Tade sold 15,000 shares of the company's stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares of the company's stock, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now directly owns 153,941 shares of the company's stock, valued at $2,843,290.27. This represents a 5.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.70% of the company's stock.

ADMA Biologics Stock Performance

Shares of ADMA stock traded up $0.50 during trading on Friday, reaching $19.82. The company had a trading volume of 2,164,386 shares, compared to its average volume of 3,287,482. ADMA Biologics, Inc. has a one year low of $3.60 and a one year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm's 50 day simple moving average is $19.10 and its two-hundred day simple moving average is $15.76. The company has a market capitalization of $4.69 billion, a PE ratio of 70.79 and a beta of 0.70.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The company had revenue of $119.84 million during the quarter, compared to analysts' expectations of $107.25 million. During the same period in the prior year, the company earned $0.01 earnings per share. Sell-side analysts forecast that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Analysts Set New Price Targets

ADMA has been the subject of several recent analyst reports. HC Wainwright raised their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, November 8th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. Finally, Raymond James raised their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.